Cargando…
Complement and platelets: prothrombotic cell activation requires membrane attack complex–induced release of danger signals
Complement activation in the diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) results in cytolysis and fatal thrombotic events, which are largely refractory to anticoagulation and/or antiplatelet therapy. Anticomplement therapy, however, efficiently pr...
Autores principales: | Mannes, Marco, Pechtl, Veronika, Hafner, Susanne, Dopler, Arthur, Eriksson, Oskar, Manivel, Vivek Anand, Wohlgemuth, Lisa, Messerer, David Alexander Christian, Schrezenmeier, Hubert, Ekdahl, Kristina N., Nilsson, Bo, Jacobsen, Eva-Maria, Hoenig, Manfred, Huber-Lang, Markus, Braun, Christian K., Schmidt, Christoph Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625899/ https://www.ncbi.nlm.nih.gov/pubmed/37428869 http://dx.doi.org/10.1182/bloodadvances.2023010817 |
Ejemplares similares
-
Dangerous B-cell clones
por: Greinacher, Andreas, et al.
Publicado: (2022) -
SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb
por: Rajagopal, Vaishnavi, et al.
Publicado: (2023) -
An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
por: Roider, Tobias, et al.
Publicado: (2021) -
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment
por: Bourne, Christopher M., et al.
Publicado: (2022) -
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
por: Lecomte, Sara, et al.
Publicado: (2023)